Medium materiality6/10
Ascendis Pharma price target raised to $290 from $280 at RBC Capital
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Target remains above the current price, indicating upside.
- Target $290 vs posted price $247.07.
Key facts
- 01
Target: $290
- 02
Posted price: $247.07
- 03
Analyst firm: RBC Capital
- 04
Analyst: Luca Issi
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.